News
Katherine Vandebelt, Brand Insights Contrib., Global Head of Clinical Innov., Oracle Health Sciences
Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...
Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.
Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...
Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...
Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...
Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...
Ted Sweetser discusses how the technology is providing greater insight into how marketing materials are being viewed.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
The FDA has granted Priority Review status to Regeneron’s and Bayer’s supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The application seeks to expand use ...
Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...
Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback